ClinicalTrials.gg
CompletedNCT01133977Updated Oct 10, 2016Results posted

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

A Phase 1/2 interventional study of Lenvatinib and Lenvatinib in Stage IV Melanoma, sponsored by Eisai Inc.. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-10.

Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing lenvatinib in Melanoma — 3 open to participants now, 5 under way, none of them phase 3. lenvatinib · Melanoma.

Enrollment
7th of 18
97 · median 41
Started
2010
with 1 other
Phase 1/2
3 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
3 of 18
Eisai Inc.

Among the 18 studies testing lenvatinib in Melanoma, this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 3 in phase 1/2, and was the 2nd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 18 studies testing lenvatinib in Melanoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing lenvatinib in Melanoma, or all of them as a file.
02

Study summary

Primary:

  • Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of lenvatinib administered in combination with dacarbazine.
  • Phase II: To evaluate the safety and tolerability of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

Secondary:

-Phase II: To make a preliminary assessment of the efficacy of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

Read the detailed description

Safety was assessed by monitoring and recording all treatment emergent adverse events (AEs) and serious adverse events (SAEs); regular monitoring of clinical laboratory parameters; periodic measurement of vital signs and electrocardiograms (ECGs); dose limiting toxicities; performance of physical examinations; concomitant medications and procedures.

03

Conditions studied

  • Stage IV Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with -confirmed melanoma (Stage IV, American Joint Committee on Cancer (AJCC)).
  2. No prior cytokine, chemotherapy, or targeted therapy for Stage IV melanoma.
  3. (ECOG) Performance Status of 0 or 1.
  4. greater than or equal to 3 months.
  5. At least 1 site of by 1.1.
  6. Adequate hematologic, renal, liver, and coagulation system function as defined by laboratory values performed within 21 days prior to initiation of dosing.
  7. Blood pressure must be well-controlled (less than or equal to 140/90 mmHg at screening) with or without antihypertensive medication. Patients must have no history of hypertensive crisis or hypertensive encephalopathy.

Exclusion criteria

Exclusion Criteria:

  1. Known central nervous system (CNS) lesions, except for asymptomatic, nonprogressive, treated . Treatment for brain metastases must have been completed at least 4 weeks prior to Day 1 and may include whole brain radiotherapy (WBRT), radiosurgery [RS; Gamma Knife, linear accelerator (LINAC), or equivalent] or a combination as deemed appropriate by the treating physician. Dexamethasone must be discontinued at least 3 weeks prior to Day 1. Patients with CNS metastases treated by neurosurgical resection or brain performed within 3 months prior to Day 1 will be excluded.
  2. Lactate dehydrogenase greater than or equal to 2.0 x (ULN).
  3. Subjects with proteinuria greater than 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with 24-hour urine protein greater than or equal to 1 g/24 hours will be ineligible.
  4. Pregnant, breast-feeding, or refusing double barrier , oral contraceptives or avoidance of pregnancy measures.
  5. Other active .
  6. History of or known carcinomatous meningitis.
  7. History of or known ocular melanoma.
  8. Are currently receiving any other treatment for the tumor (including palliative radiotherapy) aside from control of symptoms.
  9. Received treatment in another clinical study within the 30 days prior to commencing study treatment or patients who have not recovered from side effects of an drug to grade less than or equal to 1, except for alopecia.
  10. Received radiotherapy within the 30 days prior to commencing study treatment or have not recovered from side effects of all radiation-related toxicities to grade less than or equal to 1, except for alopecia.
  11. Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury within the 28 days prior to commencing study treatment. Minor surgery such as Portacath placement or skin biopsy is permitted if greater than or equal to 7 days have passed.
  12. History of bleeding diathesis or coagulopathy.
  13. Current use of anti-coagulants such as Vitamin K antagonists, unfractionated heparin, or low molecular weight heparin.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Lenvatinib + Dacarbazine (Phase 1b)

    Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine

    Drug: Lenvatinib · Drug: Dacarbazine

  • Experimental
    Lenvatinib + Dacarbazine (Phase 2)

    Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine

    Drug: Lenvatinib · Drug: Dacarbazine

  • Active comparator
    Dacarbazine (Phase 2)

    Participants received dacarbazine

    Drug: Dacarbazine

Interventions

  • Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle

    Also known as: E7080

  • Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle

    Also known as: E7080

  • Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.

    Also known as: Dacarbazine (DTIC)-Dome

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)

    DLTs were defined as clinically significant adverse events (AEs) occurring less than or equal to 21 days after commencing study treatment and considered by the Investigator to be possibly or probably related to study treatment.

    Time frame: From Day 1 through 21 days (one cycle)

  2. Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)

    Safety assessments consisted of monitoring and recording all AEs, including all Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) grades, and SAEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. Details of AEs and SAEs are provided in the reported adverse event section.

    Time frame: From signing of informed consent up to 30 days after the last dose, up to approximately 2 years

Secondary outcomes

  1. Progression Free Survival (PFS) (for Phase 2)

    PFS was defined as the time from the date of randomization of a participant until (1) the date of first documented progression of such participant's disease based on Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST v. 1.1) or (2) the date of such participant's death due to any cause. Progression was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions, based on Investigator assessment according to RECIST 1.1. If missing assessments, imputed dates were used in the analysis.

    Time frame: From the date of randomization until the date of disease progression or death (whichever was earlier) or up to approximately 2 years

Other outcomes

  1. Time to Progression (TTP) (for Phase 2)

    TTP, defined as the time from the date of randomization until the date of progressive disease.

    Time frame: From the date of randomization until disease progression or death or up to approximately 2 years

  2. Overall Survival (OS) (for Phase 2)

    OS, defined as the time from the date of randomization until the date of death. Few events of deaths (9 events in the Lenvatinib + Dacarbazine arm and 4 events in the Dacarbazine arm) were reported to calculate the median OS or to draw conclusions regarding the OS.

    Time frame: From the date of randomization until death or up to approximately 2 years

  3. Overall Response Rate (ORR) (for Phase 2)

    ORR, defined as percentage of participants with best confirmed response (complete response \[CR\] or partial response \[PR\]). A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded.

    Time frame: From the date of randomization until disease progression or death or up to approximately 2 years

07

Results

Posted Oct 10, 2016

Participant flow

A total of 16 participants were enrolled in the Phase 1b portion of the study; all 16 participants received study treatment. A total of 82 participants were randomized in the Phase 2 portion of the study and a total of 81 participants received treatment. In the Darcarbazine arm, one participant withdrew consent prior to receiving study treatment.

Participant flow — Overall Study
Milestone16 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 1b)22 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 2)Dacarbazine (Phase 2)
Started3764239
Completed00031
Not completed3763938
Withdrew: Adverse event00100
Withdrew: Death11173
Withdrew: Started a new line of therapy2642533
Withdrew: Lost to follow-up00021
Withdrew: Withdrawal by subject00051

Outcome measures

PrimaryDose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)

DLTs were defined as clinically significant adverse events (AEs) occurring less than or equal to 21 days after commencing study treatment and considered by the Investigator to be possibly or probably related to study treatment.

Time frame:
From Day 1 through 21 days (one cycle)
Reported as:
Number · Participants with DLT
Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)
Participants with DLT16 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 1b)22 mg Lenvatinib + Dacarbazine (Phase 1b)
Participants with DLTs012
Grade 3 hypertension011
Grade 3 febrile neutropenia001
Grade 3 thrombocytopenia001
PrimaryNumber of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)

Safety assessments consisted of monitoring and recording all AEs, including all Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) grades, and SAEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. Details of AEs and SAEs are provided in the reported adverse event section.

Time frame:
From signing of informed consent up to 30 days after the last dose, up to approximately 2 years
Reported as:
Number · Participants
Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)
Participants16 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 1b)22 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 2)Dacarbazine (Phase 2)
AEs3764031
SAEs242161
SecondaryProgression Free Survival (PFS) (for Phase 2)

PFS was defined as the time from the date of randomization of a participant until (1) the date of first documented progression of such participant's disease based on Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST v. 1.1) or (2) the date of such participant's death due to any cause. Progression was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions, based on Investigator assessment according to RECIST 1.1. If missing assessments, imputed dates were used in the analysis.

Time frame:
From the date of randomization until the date of disease progression or death (whichever was earlier) or up to approximately 2 years
Reported as:
Median · Weeks
Progression Free Survival (PFS) (for Phase 2)
Weeks20 mg Lenvatinib + Dacarbazine (Phase 2)Dacarbazine (Phase 2)
Progression Free Survival (PFS) (for Phase 2)19.1 (9.57 to 25.57)7.0 (5.57 to 15.57)
Statistical analysis
  • 20 mg Lenvatinib + Dacarbazine (Phase 2) vs Dacarbazine (Phase 2) · Hazard ratio (hr): 0.4 · 95% CI 0.23 to 0.75
Other pre-specifiedTime to Progression (TTP) (for Phase 2)

TTP, defined as the time from the date of randomization until the date of progressive disease.

Time frame:
From the date of randomization until disease progression or death or up to approximately 2 years

Results for this outcome have not been posted.

Other pre-specifiedOverall Survival (OS) (for Phase 2)

OS, defined as the time from the date of randomization until the date of death. Few events of deaths (9 events in the Lenvatinib + Dacarbazine arm and 4 events in the Dacarbazine arm) were reported to calculate the median OS or to draw conclusions regarding the OS.

Time frame:
From the date of randomization until death or up to approximately 2 years

Results for this outcome have not been posted.

Other pre-specifiedOverall Response Rate (ORR) (for Phase 2)

ORR, defined as percentage of participants with best confirmed response (complete response \[CR\] or partial response \[PR\]). A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded.

Time frame:
From the date of randomization until disease progression or death or up to approximately 2 years

Results for this outcome have not been posted.

Adverse events

Collected over From signing of informed consent up to 30 days after the last dose, up to approximately 2 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
16 mg Lenvatinib + Dacarbazine (Phase 1b)—2/3 (66.7%)3/3 (100%)
20 mg Lenvatinib + Dacarbazine (Phase 1b)—4/7 (57.1%)7/7 (100%)
22 mg Lenvatinib + Dacarbazine (Phase 1b)—2/6 (33.3%)6/6 (100%)
20 mg Lenvatinib + Dacarbazine (Phase 2)—16/42 (38.1%)40/42 (95.2%)
Dacarbazine (Phase 2)—1/39 (2.6%)31/39 (79.5%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
Event16 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 1b)22 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 2)Dacarbazine (Phase 2)
Cardiac Failure CongestiveCardiac disorders1/30/70/60/420/39
IleusGastrointestinal disorders1/30/70/60/420/39
AstheniaGeneral disorders1/30/70/60/420/39
FatigueGeneral disorders1/30/70/60/420/39
White Blood Cell Count IncreasedInvestigations1/30/70/60/420/39
DehydrationMetabolism and nutrition disorders1/30/70/60/420/39
Febrile NeutropeniaBlood and lymphatic system disorders0/30/71/60/420/39
ThrombocytopeniaBlood and lymphatic system disorders0/30/71/61/420/39
Abdominal PainGastrointestinal disorders0/30/71/61/420/39
Back PainMusculoskeletal and connective tissue disorders0/31/71/60/420/39
Most frequent other events
Showing 10 of 116
Most frequent other events
Event16 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 1b)22 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 2)Dacarbazine (Phase 2)
HYPERTENSIONVascular disorders1/36/75/620/422/39
NAUSEAGastrointestinal disorders2/35/74/616/4211/39
FATIGUEGeneral disorders2/35/72/610/427/39
DECREASED APPETITEMetabolism and nutrition disorders1/35/70/610/421/39
NEUTROPENIABlood and lymphatic system disorders2/33/72/610/424/39
THROMBOCYTOPENIABlood and lymphatic system disorders2/33/72/65/421/39
ABDOMINAL PAIN UPPERGastrointestinal disorders2/33/71/66/421/39
VOMITINGGastrointestinal disorders2/34/70/610/424/39
URINARY TRACT INFECTIONInfections and infestations2/30/70/64/423/39
WEIGHT DECREASEDInvestigations2/31/70/63/420/39

Baseline characteristics

A total of 40 participants were randomized in Dacarbazine (Phase 2) arm but only 39 participants received study drug and were included in the safety analysis set.

Age, Customized
Age, Customized(Participants)16 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 1b)22 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 2)Dacarbazine (Phase 2)Total
18 years and older376423997
Sex/Gender, Customized
Sex/Gender, Customized(participants)16 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 1b)22 mg Lenvatinib + Dacarbazine (Phase 1b)20 mg Lenvatinib + Dacarbazine (Phase 2)Dacarbazine (Phase 2)Total
Male324252357
Female052171640
08

Study locations

27 sites
  • Hagerstown, Maryland, United States
  • Albany, New York, United States
  • Greenville, South Carolina, United States
  • Dallas, Texas, United States
  • Norfolk, Virginia, United States
  • Berlin, 10249, Germany
  • Berlin, 12351, Germany
  • Berlin, 13585, Germany
  • Heidelberg, 69120, Germany
  • Muenchen, 81675, Germany
  • Bari, 70126, Italy
  • Milan, 20133, Italy
  • Milian, 20141, Italy
  • Napoli, 80131, Italy
  • Siena, 53100, Italy
  • Barcelona, Spain
  • Madrid, 28033, Spain
  • Madrid, 28034, Spain
  • Madrid, 28050, Spain
  • Valenica, 46014, Spain
  • Dorset, United Kingdom
  • Glasgow, United Kingdom
  • Manchester, United Kingdom
  • Middlesex, United Kingdom
  • Oxford, United Kingdom
  • Southampton, United Kingdom
  • Wirral, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Jun 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 2 years 4 months after primary completion. A results delay was requested in Aug 2014.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2010
First posted
May 31, 2010
Start
Apr 2010
Primary completionActual
Jun 2014
CompletionActual
Nov 2014
Results delay requested
Aug 19, 2014
Results first posted
Oct 10, 2016
Last update
Oct 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01133977
Lead sponsor
Eisai Inc.
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
May 31, 2010
Start date
Apr 2010
Primary completion
Jun 2014
Completion
Nov 2014
Results posted
Oct 10, 2016
Last update
Oct 10, 2016

Study contacts

Dave Harish
study director · Quintiles, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion